VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!
Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. We expect most of the near term milestones related to Earnings, Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. programs to have a positive impact on the stock price. For more details, please read our report released on 25th October, 2011 on VRTX titled “HCV/HIV Co-Infection – An Untapped Opportunity!”
COMPANIES MENTIONED
VERTEX
VERTEX
